Sanofi-Aventis agreed to pay as much as $560 million to acquire TargeGen, a San Diego developer of small-molecule kinase inhibitors designed to treat blood diseases, to boost its pipeline of cancer drugs. Sanofi will pay $75 million at the closing of the deal, which is expected this quarter.

Full Story:

Related Summaries